Inatherys

Executive Summary

Inatherys, a French biotechnology company spun out from INSERM in 2009, is developing monoclonal antibody therapies for advanced cancers and severe inflammatory diseases. Its lead candidate, INA03, targets the transferrin receptor (CD71) to inhibit tumor growth by blocking iron uptake, while INA02 targets CD89 to modulate immune responses in inflammatory conditions. Both programs are in preclinical stages, with no clinical data yet available. The company leverages a deep understanding of receptor biology to differentiate its approach from competitors. However, the early stage of development and lack of disclosed funding or partnerships introduce significant risk. Inatherys operates in a competitive landscape of antibody-based therapeutics, but its novel targets may offer unique advantages if successfully translated.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data for INA0370% success
• Q1 2027IND Filing for INA0260% success
• H2 2026Partnership or Licensing Deal50% success